TIMolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (TIM-HHT)-A Prospective, Randomized, Double-Blind, Controlled, Cross-Over Trial

• Ngā kaituhi matua: Kornelia E. C. Andorfer (Author), Florian Zeman (Author), Michael Koller (Author), Judith Zeller (Author), René Fischer (Author), Caroline T. Seebauer (Author), Veronika Vielsmeier (Author), Christopher Bohr (Author), Thomas S. Kühnel (Author)
• Hōputu: Pukapuka
• I whakaputaina: MDPI AG, 2022-10-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

To date, there is no approved local therapeutic agent for the treatment of epistaxis due to hereditary hemorrhagic telangiectasia (HHT). Several case reports suggest the topical use of timolol. This monocentric, prospective, randomized, placebo-controlled, double-blinded, cross-over study investigat...